{"id":"immediate-release-sublingual-buprenorphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sweating"}]},"_chembl":{"chemblId":"CHEMBL2368861","moleculeType":"Small molecule","molecularWeight":"504.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine acts as a partial agonist at the mu-opioid receptor, meaning it produces submaximal effects compared to full agonists like morphine. The sublingual immediate-release formulation allows rapid absorption through oral mucosa, providing faster onset of action. The partial agonist profile creates a safety ceiling for respiratory depression, making it suitable for opioid use disorder treatment with lower overdose risk than full opioids.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:13.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"},{"name":"Acute pain management"},{"name":"Opioid withdrawal"}]},"trialDetails":[{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT04234516","phase":"PHASE4","title":"Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2020-01-20","conditions":"Opioid-use Disorder, Suicidal Ideation","enrollment":""},{"nctId":"NCT01946555","phase":"","title":"Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2013-09","conditions":"Tumor, Cancer Pain, Breakthrough Cancer Pain","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Suboxone"],"phase":"marketed","status":"active","brandName":"Immediate Release Sublingual Buprenorphine","genericName":"Immediate Release Sublingual Buprenorphine","companyName":"Royal Victoria Hospital, Canada","companyId":"royal-victoria-hospital-canada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression. Used for Opioid use disorder maintenance treatment, Acute pain management, Opioid withdrawal.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}